Progen Presents Positive Data From Phase II Liver Cancer Study
Posted on: Monday, 5 November 2007, 12:00 CST
Australia-based Progen Pharmaceuticals has announced positive findings from the Phase II liver cancer study of its novel anticancer compound with a first-in-class mechanism as a heparan sulfate mimetic.
As the Phase II trial's study period covered 48 weeks from curative surgery, the data analysis was performed to evaluate the treatment's impact when patients with a low risk of experiencing a liver cancer recurrence within 12 months are removed from the analysis population.
The resultant analysis of those patients who had a high risk of recurrence in the 12-month period shows that the drug, PI-88, at least doubled the time to disease recurrence calculated at the 60th percentile (p=0.0107) (control (n=33): 24 weeks versus 160mg PI-88 (n=36): 48 weeks). This compares to a 76% improvement at the 70th percentile (p=0.0867) if all patients are included.
The double-blind placebo-controlled Phase III study is designed to assess, as its primary endpoint, improvement in disease free survival, among approximately 600 patients in countries across North America, Europe and Asia, following surgery to remove liver cancer tumors. Half of the patients in this study will be administered PI-88 after surgical removal of tumors and the remaining patients will receive a placebo so that a direct statistical comparison between the placebo and PI-88 can be made.
Source: Datamonitor
Related Articles
- REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
- Sub-Analysis of Phase III Suggests Long-Term Therapy May Improve Physical and Social Functioning In CIDP Patients
- Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
- Opexa Therapeutics Announces Completion of Mid Study Descriptive Analysis on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis
- Progen Presents Additional Analysis of Data From PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
- First Patient Registered in Investigator-Sponsored Phase 2 Trial of Antigenics' Oncophage Cancer Vaccine in Glioma
- Nuvelo Announces Completion of Patient Enrollment in SONOMA-2, First Phase 3 Trial of Alfimeprase in Central Venous Catheter Occlusion
- Bayhill Therapeutics Doses Patients With Multiple Sclerosis in a Phase II Trial and Raises an Additional $15.8 Million As an Extension to Its Series B Financing
- Cerus Seeks to Move Cancer Drug into Phase I
- First Patient Enrolled in Investigator-Sponsored Phase 1/2 Trial of Antigenics' Oncophage Cancer Vaccine in Glioma
 |
 |
User Comments (0)
RSS Feeds